【摘要】：目的:丙型肝炎是由丙型肝炎病毒感染引起的病毒性傳染病,危害較大,治療困難,目前尚無(wú)有效疫苗進(jìn)行預(yù)防,是世界主要衛(wèi)生問(wèn)題之一。本論文對(duì)一系列具有抗丙型肝炎病毒活性的化合物進(jìn)行了研究,旨在構(gòu)建高效的計(jì)算模型,為設(shè)計(jì)和篩選具有抗丙型肝炎病毒活性的新型化合物結(jié)構(gòu)提供指導(dǎo)。方法:本論文運(yùn)用計(jì)算機(jī)輔助藥物設(shè)計(jì)方法對(duì)兩類具有抗丙型肝炎病毒活性的化合物結(jié)構(gòu)進(jìn)行了相關(guān)研究。首先采用三維定量構(gòu)效關(guān)系方法構(gòu)建計(jì)算模型,分析影響化合物活性的重要結(jié)構(gòu)特征,再運(yùn)用分子對(duì)接方法對(duì)化合物在活性位點(diǎn)部位的優(yōu)勢(shì)構(gòu)象進(jìn)行分析,初步探討作用機(jī)理。在此基礎(chǔ)上,設(shè)計(jì)和篩選具有抗丙型肝炎病毒活性的新型化合物結(jié)構(gòu)。最后,利用計(jì)算軟件OSIRIS Property Explorer對(duì)具有較高活性的化合物進(jìn)行毒性及類藥性等評(píng)價(jià)。結(jié)果:1、用三維定量構(gòu)效關(guān)系方法對(duì)42個(gè)4-羥氨基α-吡喃酮甲酰胺類似物進(jìn)行了研究,建立了可靠性和預(yù)測(cè)能力較高的QSAR模型(q~2=0.569,r~2=0.904,F值為20.756,SEE=0.135,R_(ext)~2=0.653,r_(boot)~2=0.955,SEE_(boot)=0.091,R_p~2=0.609,R_(m(overall))~2=0.680)。通過(guò)等勢(shì)圖分析了影響抑制劑活性的結(jié)構(gòu)特征,在此基礎(chǔ)上設(shè)計(jì)并篩選了103個(gè)具有抗丙型肝炎病毒活性的新型化合物結(jié)構(gòu),同時(shí)對(duì)化合物的活性進(jìn)行了預(yù)測(cè)。此外,利用計(jì)算軟件OSIRIS Property Explorer對(duì)40個(gè)活性較高的化合物結(jié)構(gòu)進(jìn)行了毒性及類藥性等評(píng)價(jià)。通過(guò)綜合分析,2578號(hào)化合物為最優(yōu)結(jié)構(gòu)。2、基于三維定量構(gòu)效關(guān)系和分子對(duì)接方法對(duì)48個(gè)HCV NS5B聚合酶抑制劑進(jìn)行了研究�；诨衔锝Y(jié)構(gòu)和活性構(gòu)建了QSAR模型,并對(duì)最優(yōu)模型進(jìn)行了驗(yàn)證(q~2=0.627,r~2=0.943,F值為86.182,SEE=0.221,R_(ext)~2=0.629,r_(boot)~2=0.975,SEE_(boot)=0.141,R_p~2=0.697,R_(m(overall))~2=0.835),結(jié)果說(shuō)明該模型具有可靠性和較高的預(yù)測(cè)能力。通過(guò)等勢(shì)圖和分子對(duì)接結(jié)果對(duì)影響抑制劑活性的結(jié)構(gòu)特征進(jìn)行分析,設(shè)計(jì)并篩選了136個(gè)具有抗丙型肝炎病毒活性的新型化合物結(jié)構(gòu),同時(shí)對(duì)這些化合物的活性進(jìn)行預(yù)測(cè)。通過(guò)計(jì)算軟件OSIRIS Property Explorer對(duì)具有較高抑制活性的43個(gè)化合物結(jié)構(gòu)進(jìn)行了毒理性質(zhì)及類藥性等評(píng)價(jià)。通過(guò)綜合分析,130號(hào)化合物為最優(yōu)結(jié)構(gòu)。結(jié)論:本論文中,三維定量構(gòu)效關(guān)系和分子對(duì)接等計(jì)算機(jī)輔助藥物設(shè)計(jì)方法的結(jié)合應(yīng)用,可對(duì)兩類具有抗丙型肝炎病毒活性的化合物進(jìn)行較為系統(tǒng)的研究。通過(guò)分析影響化合物抑制活性的結(jié)構(gòu)特征,為設(shè)計(jì)具有抗丙型肝炎病毒活性的新型化合物結(jié)構(gòu)提供了一定的指導(dǎo),為丙型肝炎藥物的研發(fā)和篩選提供了理論依據(jù)和新的思路。
[Abstract]:Objective: hepatitis C is a viral infectious disease caused by hepatitis C virus infection, which is harmful and difficult to treat. At present, there is no effective vaccine to prevent hepatitis C, which is one of the major health problems in the world. In this paper, a series of compounds with anti-HCV activity were studied in order to construct an efficient computational model and provide guidance for the design and screening of novel compounds with anti-HCV activity. Methods: the structures of two kinds of compounds with anti-HCV activity were studied by computer-aided drug design. Firstly, a three-dimensional quantitative structure-activity relationship method was used to construct a computational model to analyze the important structural characteristics affecting the activity of the compounds. Then, the molecular docking method was used to analyze the dominant conformation of the compounds at the active sites, and the mechanism of action was preliminarily discussed. On this basis, a novel compound structure with anti-HCV activity was designed and screened. Finally, OSIRIS Property Explorer was used to evaluate the toxicity and drug-like properties of the compounds with high activity. Results: 1. 42 4-hydroxyamino 偽 -pyrroanone formamide analogues were studied by three-dimensional quantitative structure-activity relationship. QSAR models with high reliability and predictive ability were established. The QSAR model was established (the F value of QU2H2A0. 569NV 0.904F was 20.756Se ~ 0.135R _ (ext) ~ 20.653r- (boot) ~ 20.955SEE _ (boot) = 0.091Rpp2O0.609R _ (m (overall) ~ 20.680). The results showed that: (1) the quantitative structure-activity relationship was used to study 42 4-hydroxyamino 偽 -pyranone formamide analogues, and the QSAR model was established with high reliability and predictive ability. Based on the analysis of the structural characteristics of the inhibitors, 103 novel compounds with anti-HCV activity were designed and screened, and the activity of the compounds was predicted. In addition, the toxicity and drug-like properties of 40 compounds with high activity were evaluated by OSIRIS Property Explorer. Based on the quantitative structure-activity relationship and molecular docking method, 48 HCV NS5B polymerase inhibitors were studied. The QSAR model was constructed based on the structure and activity of the compound, and the optimal model was verified (the value of Q _ 2O _ (0.627) ~ (?) ~ (0.943) F is 86.182 QSAR ~ (0.221) (ext) ~ (2). The result shows that the model is reliable and has high predictive ability. The results show that the model is reliable and has a high predictive ability. The results show that the model is reliable and has high predictive ability. Based on the isopotential diagram and molecular docking results, 136 novel compounds with anti-HCV activity were designed and screened, and the activity of these compounds was predicted. The toxicological properties and drug-like properties of 43 compounds with high inhibitory activity were evaluated by computer software OSIRIS Property Explorer. The optimum structure of compound 130 was found by comprehensive analysis. Conclusion: in this paper, the combination of three-dimensional quantitative structure-activity relationship and molecular docking can be used to study two kinds of compounds with anti-HCV activity. By analyzing the structural characteristics of the inhibitory activity of the compounds, it provides some guidance for the design of new compounds with anti-hepatitis C virus activity, and provides a theoretical basis and a new way of thinking for the development and screening of hepatitis C drugs.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R91

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 崔坡;孔麗;趙素賢;;丙型肝炎的直接抗病毒藥物[J];臨床薈萃;2016年07期

2 趙文濤;孟令軍;趙好好;王春春;;樸素貝葉斯算法的改進(jìn)與應(yīng)用[J];測(cè)控技術(shù);2016年02期

3 任姍;陳新月;;丙型肝炎相關(guān)直接抗病毒藥物耐藥的研究現(xiàn)狀[J];臨床肝膽病雜志;2015年11期

4 王宏亮;曹爽;;抗丙型肝炎病毒藥物研究的新進(jìn)展[J];臨床藥物治療雜志;2015年06期

5 王靖;何小羊;;抗丙型肝炎病毒藥物研究進(jìn)展[J];國(guó)際藥學(xué)研究雜志;2015年05期

6 ;丙型肝炎防治指南(2015年更新版)[J];中華實(shí)驗(yàn)和臨床感染病雜志(電子版);2015年05期

7 阮夢(mèng)黎;;基因表達(dá)式編程的種群多樣性優(yōu)化策略與應(yīng)用[J];山東師范大學(xué)學(xué)報(bào)(自然科學(xué)版);2015年03期

8 盧捷;謝青;;直接抗病毒藥物治療丙型肝炎的研究新進(jìn)展[J];臨床內(nèi)科雜志;2015年08期

9 劉毅娟;雷鳴;何e，

本文編號(hào)：2294390